A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 999-1005

  Veronesi, Maddalena ^a   Cicero, Arrigo F G ^a   Prandin, Maria Grazia ^a   Dormi, Ada ^a   Cosentino, Eugenio ^a   Strocchi, Enrico ^a   Borghi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antihypertensive drugs; Blood pressure; Hypertension; Persistence

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LERCANIDIPINE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREND STUDY; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 38149039304     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ambrosioni E, Leonetti G, Pessina AC, et al. 2000. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens, 18:1691-9.
2. Bang LM, Chapman TM, Goa KL. 2003. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs, 63:2449-72.
3. Basile J. 2004. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens, 6:621-29.
4. Beckey C, Lundy A, Lutfi N. 2007. Lercanidipine in the treatment of hypertension. Ann Pharmacother, 41:465-73.
5. Black DM, Brand RJ, Greenlick M, et al. 1987. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. J Gerontol, 42:552-7.
6. Blooms BS. 1998. Continuation of initial antihypertensive medication after 1-year of therapy. Clin Ther, 20:671-81.
7. Borghi C, Dormi A, D'Addato S, et al. 2004. Brisighella Heart Study Working Party. 2004. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens, 22:1707-16.
8. Borghi C. 2005. Lercanidipine in hypertension. Vasc Health Risk Manag, 1:173-82.
9. Burnier M, 2006. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens, 19:1190-6.
10. David DS. 2006. Compliance with hypertensive therapy. Hypertension, 48:E16.
11. Erdine S, Ari O, Zanchetti A, et al. 2006. ESH-ESC guidelines for the management of hypertension. Herz, 31:331-8.
12. ESH-ESC. 2003. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J Hypertens, 21:1011-53.
13. Fujita T, Shimamoto K, Wu Z, et al. 2006. What are the major challenges in getting patients to the optimal BP goal? Difficulties in educating doctors and patients. Int J Clin Pract Suppl, 150:20-2.
14. Grimm RH Jr, Grandits GA, Cutler JA, et al. 1997. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med, 157:638-48.
15. JNC VII, 2003. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206-52.
16. Jones JK, Gorkin L, Lian JF, et al. 1995. Discontinuation or and changes in treatment after start or new courses or antihypertensive drugs: a study or a United Kingdom population. BMJ, 311:293-5.
17. McCombs IS, Nichol MB, Newman CM, et al. 1994. The costs or interrupting antihypertensive drug therapy in a Medicaid Population. Med Care, 32:214-26.
18. Messerli FH. 2002. Calcium antagonists in hypertension: from hemodynamics to outcomes. Am J Hypertens, 15:94S-97S.
19. Monane M, Bohn RL, Gurwitz JH, et al. 1997. The effects or initial drug choice and comorbidity on antihypertensive therapy compliance: Results from a population based study in the elderly. Am J Hypertens, 10:697-704.
20. Okano GJ, Rascati KL, Wilson JP, et al. 1997. Patterns or antihypertensive use among patients in the US Department or Defence database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker. Clin Ther, 19:1433-44.
21. Poluzzi E, Strahinja P, Vargiu A, et al. 2005. Initial treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol, 61:603-9.
22. SHEP Cooperative Research Group. 1991. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 265:3255-64.
23. Staessen JA, Li Y, Thijs L, et al. 2005. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res, 28:385-407.
24. Wolf-Maier K, Cooper RS, Kramer H, et al. 2004. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension, 43:10-17.